Rigel Pharmaceuticals Inc (RIGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has a cash flow conversion efficiency ratio of 0.007x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.73 Million) by net assets ($399.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Rigel Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Rigel Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Rigel Pharmaceuticals Inc (RIGL) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Rigel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
-0.015x |
|
MH Robot & Automation Co. Ltd.
SHE:301199
|
-0.001x |
|
China Haisum Engineering Co Ltd
SHE:002116
|
0.043x |
|
Southern First Bancshares Inc
NASDAQ:SFST
|
0.039x |
|
MediaAlpha Inc.
NYSE:MAX
|
0.053x |
|
Origin Enterprises Plc
IR:OIZ
|
0.316x |
|
KKR Credit Income Fund
AU:KKC
|
0.040x |
|
Sung Kwang Bend Co.Ltd
KQ:014620
|
0.036x |
Annual Cash Flow Conversion Efficiency for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Rigel Pharmaceuticals Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Rigel Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $391.48 Million | $75.66 Million | 0.193x | -97.98% |
| 2024-12-31 | $3.29 Million | $31.47 Million | 9.571x | +4673.90% |
| 2023-12-31 | $-28.64 Million | $-5.74 Million | 0.200x | -96.30% |
| 2022-12-31 | $-13.62 Million | $-73.76 Million | 5.417x | +2699.19% |
| 2021-12-31 | $30.37 Million | $5.88 Million | 0.194x | +112.62% |
| 2020-12-31 | $34.03 Million | $-52.19 Million | -1.534x | -98.83% |
| 2019-12-31 | $53.81 Million | $-41.51 Million | -0.771x | -44.07% |
| 2018-12-31 | $109.88 Million | $-58.83 Million | -0.535x | +30.52% |
| 2017-12-31 | $100.65 Million | $-77.56 Million | -0.771x | +44.12% |
| 2016-12-31 | $55.03 Million | $-75.89 Million | -1.379x | -438.27% |
| 2015-12-31 | $91.38 Million | $-23.41 Million | -0.256x | +52.89% |
| 2014-12-31 | $128.25 Million | $-69.75 Million | -0.544x | -31.61% |
| 2013-12-31 | $208.25 Million | $-86.06 Million | -0.413x | -40.24% |
| 2012-12-31 | $289.10 Million | $-85.19 Million | -0.295x | -0.31% |
| 2011-12-31 | $236.15 Million | $-69.38 Million | -0.294x | -204.41% |
| 2010-12-31 | $166.13 Million | $46.74 Million | 0.281x | +130.08% |
| 2009-12-31 | $109.87 Million | $-102.78 Million | -0.935x | +5.87% |
| 2008-12-31 | $104.17 Million | $-103.52 Million | -0.994x | -56.44% |
| 2007-12-31 | $82.18 Million | $-52.21 Million | -0.635x | -54.63% |
| 2006-12-31 | $87.23 Million | $-35.84 Million | -0.411x | -26.84% |
| 2005-12-31 | $108.59 Million | $-35.17 Million | -0.324x | +55.60% |
| 2004-12-31 | $52.30 Million | $-38.15 Million | -0.729x | +10.11% |
| 2003-12-31 | $39.97 Million | $-32.44 Million | -0.812x | +40.20% |
| 2002-12-31 | $25.44 Million | $-34.53 Million | -1.357x | -145.78% |
| 2001-12-31 | $28.94 Million | $-15.98 Million | -0.552x | -133.54% |
| 2000-12-31 | $49.01 Million | $-11.59 Million | -0.236x | +97.72% |
| 1999-12-31 | $756.00K | $-7.83 Million | -10.358x | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more